

9 February 2018

ASX Announcement

Penthrox approved in Latvia

Medical Developments International Limited (ASX: MVP) is delighted to announce that Penthrox has been approved for sale in Latvia.

The State Agency of Medicines of the Republic of Latvia issued the Marketing Authorisation on 25 January 2018.

MVP CEO, Mr. John Sharman said, "It is exciting to see a further Marketing Authorisation come through bringing the total approvals over the last 3 weeks to 5. We expect the remaining 17 countries will issue Marketing Authorisations to approve the sale of Penthrox in their country over the coming months."

European approval progress





Enquiries:

David Williams
Chairman
Medical Developments International Ltd
+61 (0) 414 383 593

John Sharman
Chief Executive Officer
Medical Developments International Ltd
+61 (3) 9547 1888



About Pentrox

Penthrox is a fast onset, non-opioid analgesic indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Penthrox has been used safely and effectively for more than 40 years in Australia with excess of 5.0 million units sold. There is growing interest in Penthrox being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy.

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Penthrox®, a fast acting trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.

About the Mundipharma network

The Mundipharma global network of privately-owned independent associated companies was founded in 1956 by doctors, and now operates in over 120 countries worldwide. We are focused on developing business partnerships to identify and accelerate meaningful technology across an increasingly diverse portfolio of therapy areas including respiratory, oncology, pain, and biosimilars. Consistent with our entrepreneurial heritage, we like to think we see what others don't by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems. For more information please visit: www.mundipharma.com.